TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02673320

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early surgery within 48 hours
Description: After completion of the clinical and radiological diagnosis of post-traumatic spinal cord contusion on narrow spinal canal, the patient was hospitalized. After obtaining the signed consent form, the patient was included in the protocol. After anesthetic consultation determining the feasibility or not of surgery and in the absence of other vital injury or involving life-threatening, early surgery is then realised within 48 hours. The surgical technique is a conventional cervical spinal decompression surgery. Surgery by way posterior surgery, by laminectomy in case of significant spinal stenosis greater than or equal to 3 floors will be preferred. In other cases, the type of surgery will be at the discretion of the surgeon. Then, the follow-up visits are D7, M3, Y1 and Y2.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Delayed surgery at 15 days
Description: After completion of the clinical and radiological diagnosis of post-traumatic spinal cord contusion on narrow spinal canal, the patient was hospitalized. After obtaining the signed consent form, the patient was included in the protocol. After anesthetic consultation determining the feasibility or not of surgery and in the absence of other vital injury or involving life-threatening, delayed surgery is then realised at 15 days. The surgical technique is a conventional cervical spinal decompression surgery. Surgery by way posterior surgery, by laminectomy in case of significant spinal stenosis greater than or equal to 3 floors will be preferred. In other cases, the type of surgery will be at the discretion of the surgeon. Then, the follow-up visits are D7, M3, Y1 and Y2.
Study: NCT05326360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron Hydrochloride
Description: we injected two additional remosetron doses in different way in experimental groups. In group B, patients received additional ramosetron at 12 hour interval, in group M, patients received additional ramosetron in mixed with the patient controlled analgesia regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron Hydrochloride
Description: we injected two additional remosetron doses in different way in experimental groups. In group B, patients received additional ramosetron at 12 hour interval, in group M, patients received additional ramosetron in mixed with the patient controlled analgesia regimen.
Study: NCT00343915

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B (thiomersal-free) 20µg
Description: In the primary study: 2 deep intramuscular injections (Months 0, \& 6)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 10 μg Engerix™-B (preservative-free)
Description: In the primary study: 3 deep intramuscular injections (months 0, 1 \& 6)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: placebo
Description: In the primary study: 1 deep intramuscular injection (month 1)
Study: NCT04913701

Intervention type: OTHER
Intervention: Observation group 1
Description: Subjects will be followed with 3 swabs and serological test

Intervention type: OTHER
Intervention: Observation group 1
Description: Subjects will be followed with 3 swabs and serological test

Intervention type: OTHER
Intervention: Observation group 1
Description: Subjects will be followed with 3 swabs and serological test
Study: NCT02212171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TRIAP
Description: The primary healthcare professionals organised in healthcare mini-teams, composed of 2 doctors, 2 nurses and 1 member of the administrative staff.~1. Administrative staff:~   Following a flow chart, they will refer patients with mild self-limiting illnesses as well as consultations regarding chronic disorders in adults to the nurses. They will also perform administrative tasks such as the printing of prescriptions, sick leave reports and medical notes (justifying absence), etc.~2. Nursing staff:~   They will carry out activities focused on health promotion, self-management and de-medicalisation during visits from patients with mild self-limiting illnesses as well as appointments for chronic diseases in adults.~3. GP:~They will develop the new portfolio of services: health promotion, joint review of patient medical records by doctors and nurses to improve the management of certain groups of patients, and organization of minor surgery services, etc.
Study: NCT04014621

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SPG stimulation
Description: The BrainsGate Ischemic Stroke System (ISS) consists of an implantable neurostimulator designed to deliver electrical stimulation to the sphenopalatine ganglion (SPG) and/or nerves within the greater palatine canal and pterygopalatine fossa.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SPG stimulation
Description: The BrainsGate Ischemic Stroke System (ISS) consists of an implantable neurostimulator designed to deliver electrical stimulation to the sphenopalatine ganglion (SPG) and/or nerves within the greater palatine canal and pterygopalatine fossa.
Study: NCT03577392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin + capecitabine (XELOX chemotherapy)
Description: Oxaliplatin(130mg/m2 over 2h)was intravenously administated for at least 2h on day 1. Capecitabine(1000mg/m2 twice daily)was oral administrated from the evening of day 1 to the morning of day 15.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin + capecitabine (XELOX chemotherapy)
Description: Oxaliplatin(130mg/m2 over 2h)was intravenously administated for at least 2h on day 1. Capecitabine(1000mg/m2 twice daily)was oral administrated from the evening of day 1 to the morning of day 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rebombniant human endostatin
Description: Endostar is a recombinat human endostatin with antiangiogenic properties that has been useful in treating a wide range of cancers and shows promise for use in combination treatment for advanced colorectal cancer. The dose of Recombinant human endostatin on day -5 was calculated according to the patients's body surface area, to provide a CIV 7 days' dose in physiological saline to 240mL volume.
Study: NCT01342549

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproate
Description: 250mg per day 30 minutes after a meal. Dosages will be increase as tolerated to a maximum recommended dosage of 60 mg per kg per day. Usual dosage is between 1250mg to 2000mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: 25mg per day, taken by mouth for 7 days, then 50mg per day
Study: NCT01206686

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Planning Prompt
Description: Patients were prompted to write down a planned date (and in some cases time) for receiving a flu shot.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Planning Prompt
Description: Patients were prompted to write down a planned date (and in some cases time) for receiving a flu shot.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Planning Prompt
Description: Patients were prompted to write down a planned date (and in some cases time) for receiving a flu shot.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Default Appointment
Description: Patients were given a suggested date and time for receiving a flu shot.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Patients were provided with basic information (present in all conditions) about when and where they could receive a flu shot, but they were given no further treatment.
Study: NCT04700956

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: primary abdominal closure
Description: The linea alba will be closed to a ratio of 5mm / 5mm. Only the fascia will be sutured ; fat or muscle tissue will be avoided. Subcutaneous tissue will be closed with polyglactin 3/0 suture. The skin will be closed with a stapler.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: abdominal closure with prophylactic mesh
Description: After the fascia was closed with the same method, 5 cm of subcutaneous tissue will be dissected around the incision. The mesh will be placed in the supra-aponeurotic area (onlay) to a distance of laterally and cranial-caudally 5 cm from the fascia margins. The mesh used will be partially absorbable, light and large porous. After this procedure, the borders of the mesh will be fixed circumferentially on the abdominal wall using polypropylene suture to prevent the intestines from herniating on the mesh. Two subcutaneous drainage catheters will be placed in all patients with mesh.
Study: NCT00591669

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Definity
Description: We will be placing one vial (1.3) of Definity® in 50 mL of preservative-free saline. Our infusions will be initiated at slightly lower than recommended starting rate (3mL/min) and will be adjusted as necessary to produce optimal enhancement. The rate will not exceed 10 ml/min and we will not give more than 1.3 mL of Definity® in 50mL saline in any 24-hour period.

Intervention type: OTHER
Group type: OTHER
Intervention: Definity
Description: We will be placing one vial (1.3) of Definity® in 50 mL of preservative-free saline. Our infusions will be initiated at slightly lower than recommended starting rate (3mL/min) and will be adjusted as necessary to produce optimal enhancement. The rate will not exceed 10 ml/min and we will not give more than 1.3 mL of Definity® in 50mL saline in any 24-hour period.
Study: NCT04641949

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lower body negative pressure (LBNP)
Description: LBNP is a model of experimental hypovolemia, whereby the lower body is exposed to negative pressure leading to sequestering of blood in the lower body and central hypovolemia. LBNP will be induced stepwise with increments of 10 mmHg, each level lasting 1 min. LBNP will be terminated at symptoms or signs of impending hemodynamic collapse.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lower body negative pressure (LBNP)
Description: LBNP is a model of experimental hypovolemia, whereby the lower body is exposed to negative pressure leading to sequestering of blood in the lower body and central hypovolemia. LBNP will be induced stepwise with increments of 10 mmHg, each level lasting 1 min. LBNP will be terminated at symptoms or signs of impending hemodynamic collapse.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Lower body negative pressure (LBNP)
Description: LBNP is a model of experimental hypovolemia, whereby the lower body is exposed to negative pressure leading to sequestering of blood in the lower body and central hypovolemia. LBNP will be induced stepwise with increments of 10 mmHg, each level lasting 1 min. LBNP will be terminated at symptoms or signs of impending hemodynamic collapse.
Study: NCT01740544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Description: Cathodal tDCS applied over the right PPC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Description: Cathodal tDCS applied over the right PPC

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham tDCS applied over the right PPC

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham tDCS applied over the right PPC
Study: NCT01536704

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine (4 mg)
Description: 4 mg nicotine lozenge in two formulations
Study: NCT02015845

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accuvein

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Routine technique
Description: Placement of peripheral intravenous catheters using the routine technique
Study: NCT03190902

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Processing Training program (APT)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Processing Training program (APT)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: nonspecific computer training (n-ST)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: nonspecific computer training (n-ST)
Study: NCT02542631

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bolus Insulin Patch (Calibra Finesse)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Pen (Novo-Nordisk FlexPen®)
Study: NCT02144441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glargine and aspart
Description: Inpatient will administer hospital-dispensed basal-bolus insulin (glargine and aspart) according to a regimen developed in collaboration with the diabetes consult service.
Study: NCT01536704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine (4 mg)
Description: 4 mg nicotine lozenge in two formulations
Study: NCT04353050

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Non-invasive adhesive system (patch)
Description: The already registered on the market adhesive skin patch will be applied and removed for several times on the pigmented skin (or mucosal) lesion just before the preplanned excisional biopsy after local anaesthesia have been already administered. Excisional biopsy and local anaesthesia are not the part of this study and will be carried out according to local practice
Study: NCT01539252

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single dialyzer
Description: Hemodialysis treatment using a single Baxter dialyzer - considered standard hemodialysis treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two dialyzers
Description: Hemodialysis treatment using a two Baxter dialyzers in parallel.
Study: NCT03493256

Intervention type: OTHER
Intervention: exposure to type 2 neurological complications
Description: exposure to postoperative cognitive dysfunction (POCD) or postoperative delirium (POD), or both concurrently.
Study: NCT01492920

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acetyl-L-Carnitine Hydrochloride
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT02352870

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerised Cognitive Behavioural Therapy
Description: Online treatment sessions are scheduled to last approximately one hour, completed independently by the participant on a weekly basis

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerised Cognitive Behavioural Therapy
Description: Online treatment sessions are scheduled to last approximately one hour, completed independently by the participant on a weekly basis

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone support
Description: Telephone support calls are scheduled to last 30 minutes and and are received fortnightly at weeks: 2, 4 and 6.
Study: NCT02248883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPV low

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPV high

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV
Study: NCT04683016

Intervention type: OTHER
Intervention: Questionnaires
Description: Patients will be asked two sets of questions:~* questionnaire about their perception of periodontal disease (Brief Illness Perception Questionnaire; 9 questions, answers will be registered on a scale of 0 to 10);~* Oral Health Impact Profile 14 (OHIP-14) questionnaire.~All these two sets of questions will be asked before and after non surgical periodontal therapy
Study: NCT01415102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212372
Description: Inhaled. Dose Level 1: 50 ug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212372
Description: Inhaled. Dose Level 2 - Dose to be selected based upon safety/tolerability/PK at preceding dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212372
Description: Inhaled. Dose Level 3 - Dose to be selected based upon safety/tolerability/PK at preceding dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212372
Description: Inhaled. Dose Level 4 - Dose to be selected based upon safety/tolerability/PK at preceding dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inhaled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212372
Description: Inhaled. Dose Level 5 - Dose to be selected based upon safety/tolerability/PK at preceding dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212372
Description: Inhaled. Dose Level 6 - Dose to be selected based upon safety/tolerability/PK at preceding dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212372
Description: Inhaled. Dose Level 7 - Dose to be selected based upon safety/tolerability/PK at preceding dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inhaled
Study: NCT01881984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravicti
Description: Open-label design comparing Ravicti at doses of 2, 4, and 6 grams/m2/day
Study: NCT03776149

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Description: Following randomization on day 1, subjects will consume either the nitrate or nitrate-free beverage for 7 days with outcome measurements performed on day 7. Following a 7 day washout, subjects will then consume the crossover beverage for 7 days with outcome measures performed on day 21.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Black currant juice
Description: Following randomization on day 1, subjects will consume either the nitrate or nitrate-free beverage for 7 days with outcome measurements performed on day 7. Following a 7 day washout, subjects will then consume the crossover beverage for 7 days with outcome measures performed on day 21.
Study: NCT05494476

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant insertion
Description: after flap detachment, implant bed will be prepared with twist-drill, implant will be inserted according to randomization (1 or 2 mm under bone)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant insertion
Description: after flap detachment, implant bed will be prepared with twist-drill, implant will be inserted according to randomization (1 or 2 mm under bone)
Study: NCT02220062

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-CPN
Description: After initially identifying the celiac trunk on endoscopic ultrasound, each injection of 5\~10cc ethanol would be performed as bilateral injections at the celiac trunk.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-CGN
Description: First, identify celiac ganglia. If the celiac ganglia are visualized under linear EUS, the injection of 2\~3cc ethanol are applied directly into the each ganglia. If the ganglia are not identified by EUS, bilateral EUS-CPN would be performed
Study: NCT02210845

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised exercise
Description: Supervised exercise intervention is training with professional trainers once a week. It will include aerobic exercise tailored to the individual participant.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Financially incentivized weight Loss
Description: Financially incentivized weight loss encourages participants to achieve a monthly goal weight reduction for a 50 dollars prize.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care at BCDiabetes
Description: usual care dictated by GCP at BCDiabetes.ca
Study: NCT04472676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3473329
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3473329
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.
Study: NCT03958292

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IODIM
Description: Eye drops containing polyvinylpyrrolidone-Iodine (PVP-Iodine), hyaluronic acid and triglycerides
Study: NCT00442871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag
Description: eltrombopag 50 mg oral
Study: NCT00394563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RN624 (PF-04383119)
Description: 10 mcg/kg
Study: NCT03138720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Protein Bound (Abraxane)
Description: Participants will be treated with the regimen prior to having surgery. Participants will complete 3 cycles (cycle is 21 days) and then will be evaluated for CA19-9 normalization. If CA19-9 is normalized, then participant will be scheduled for surgery and moved to standard of care. If CA19-9 is not normalized then participants will complete another 3 cycles.
Study: NCT03950726

Intervention type: PROCEDURE
Intervention: ileocolic resection
Description: Ileocolic resection through McBurney incision

Intervention type: PROCEDURE
Intervention: ileocolic resection
Description: Ileocolic resection through McBurney incision
Study: NCT01319032

Intervention type: OTHER
Intervention: Extraction of whole blood
Description: Extraction of DNA from whole blood

Intervention type: OTHER
Intervention: Extraction of whole blood
Description: Extraction of DNA from whole blood
Study: NCT01686152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod Cream, 3.75%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zyclara®

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of Test Product
Study: NCT00817648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Quetiapine fumarate, 25mg/200 mg, the dose titration is carried in week 1. flexible doses(600-750 mg/d) from week 2 to week 6. If a patient is intolerant, the doses can be adjusted as judged by investigator.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone
Description: risperidone, 1mg/tablet, the dose titration is carried in week 1. flexible doses(3-6 mg/d) from week 2 to week 6. If a patient is intolerant, the doses can be adjusted as judged by investigator.